BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 08/04/22
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)GlobeNewsWire • 07/01/22
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022GlobeNewsWire • 06/22/22
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?Zacks Investment Research • 06/20/22
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin AmericaGlobeNewsWire • 06/09/22
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema AttacksGlobeNewsWire • 06/06/22
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/22
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 05/05/22
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/22
After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?The Motley Fool • 04/19/22